Table III.

Citrulline-specific antibodies mediate arthritis relapse

mAbs	Incidence	Mean max arthritis score (mean ± SEM)
ACC4	4/9*	20 ± 3*
PBS	1/20	5
M2139 + PBS	2/7	3 ± 2
UL1 + PBS	4/8	18 ± 3
M2139 + ACC4	7/10	14 ± 2*
M2139 + CIIC1	18/20	26 ± 4
M2139 + UL1	9/9	25 ± 2
UL1 + ACC4	4/9	15 ± 6

2-mo-old QB = (BALB/c x B10.Q) F1 mice were injected with CII + CFA on day 0 and boosted with CII + IFA on day 35. These mice developed chronic arthritis that persisted for a minimum of 210 d. Mice that had no arthritis after 210 d were injected with 9 mg of a single mAb or an equal combination of two mAbs. M2139 with CIIC1 or UL1 and 4.5 mg M2139 or UL1 with PBS constituted positive and negative controls, respectively. The PBS-injected group denotes spontaneous relapse. LPS was not injected in these mice. Results shown are pooled values from two similar experiments. Cumulative incidence: ACC4 versus PBS, P ≤ 0.0093. Maximum arthritis score: M2139 + ACC4 versus M2139 + PBS, P ≤ 0.0266; and ACC4 versus PBS, P ≤ 0.0073. *, P < 0.05.